🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Mitral Valve Prolapse Arrhythmic Risk

Recruitingn/aAges any - anyAllOslo University Hospital
NCT07830888 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Mitral valve prolapse (MVP) is common with a 2-3 % prevalence in the general association and generally associated with a favorable prognosis. However, a subgroup of MVP patients, known as arrhythmic mitral valve prolapse (AMVP) has an increased burden of severe ventricular arrhythmias and risk of sudden cardiac death. Identifying high risk patients who may benefit of potential implantable cardioverter-defibrillator (ICD) implantation is therefore critically important. Risk stratification in AMVP is still challenging, and the ability to estimate arrhythmic risk at the individual level is limited.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * MVP according to the ESC definition AND * Arrhythmic burden of: * A total PVC burden ≥ 0,5 % per day OR * Documentation of NSVT on any modality OR * More severe ventricular arrhythmias (sustained ventricular tachycardia, ventricular fibrillation, aborted cardiac arrest) that occurred \>1 month after the beginning of follow up. AND \- Follow up \>6 months Exclusion Criteria: * VT/VF as the initial presentation without prior cardiac evaluation (ECG, echo, Holter) * History of myocardial infarction * Obstructive coronary diseases - ≥50 % stenosis that was not treated * History of coronary artery bypass surgery * Significant valve disease other than MVP - rheumatic heart disease, severe aortic stenosis * LGE suggestive of probable myocarditis as the etiology. * Primary inherited arrhythmia - Brugada syndrome, short QT, long QT, CPVT * Carrier of disease causing mutation known to be associated with arrhythmia even when phenotype is negative (e.g. Lamin A/C) * Sustained ventricular arrhythmia clearly caused by a reversable cause
💊

What it tests

  • Risk prediction model
📍

Where

1 site
Rikshospitalet, Oslo University Hospital
Oslo, Norway
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy